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Type 2 diabetes mellitus (T2DM) need adequate diet, exercise and pharmacotherapy. Authors have 
continued diabetic practice and research on low carbohydrate diet (LCD), calorie restriction (CR), 
continuous glucose monitoring (CGM), and so on. The case is 50-year-old female patient with T2DM for 
10 years. She has received insulin treatment with recent HbA1c 7.4 – 8.7%, then her glucose profile was 
studied on CGM by FreeStyle Libre. Treatment was changed from Glargine 15 units (until day 5) to 
Zultophy10-12 doses (after day 6), then her glucose variability showed remarkably improved. The 
average blood glucose on day 3, 5, 6, 8,10,13 was 174, 164, 125, 111, 101, 98 mg/dL, respectively. 
FreeStyle Libre showed estimated HbA1c as 6.2% and 44 mmol/mol.  
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Recently, diabetes mellitus is crucial disease to be managed and prevented adequately in the world [1]. 
When patients are in diabetic states, they will have various chronic complications, including 
microangiopathy and macroangiopathy [2]. In order to prevent and delay the diabetic progress, there are 
three kinds of principle therapies. They are nutritional therapy, exercise therapy and pharmacotherapy, 
which are universally common fundamental method in all countries [3].  
 
Regarding diabetic nutritional therapy, there have been generally two kinds. They are low carbohydrate 
diet (LCD) and calorie restriction (CR) [4]. Recently, LCD has been evaluated to be rather effective 
compared with CR in lots of reports [5,6]. In western countries, LCD became well-known by Bernstein 
and others [7]. On the other hand, authors and co-researchers have initiated LCD in Japan [8]. We have 
developed LCD medically and socially through the activity of Japan LCD promotion association (JLCDPA) 
[9]. Further, our research team continued several reports concerning daily profile of blood glucose, M 
value, elevated ketone bodies in blood, meal tolerance test (MTT) and continuous glucose monitoring 
(CGM) [10]. As to CGM, we had reported impressive diabetic cases and clinical usefulness for detecting 
hyperglycemia associated with various daily activities [11]. 
 
Authors have reported some diabetic cases with efficacy for oral hypoglycemic agents (OHAs) and/or 
injective treatment [12,13]. Recently, there are injective vials for diabetes, which are insulin and 
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glucagon-like-1 receptor agonists (GLP-1 RAs). Furthermore, one of the new topics would be the 
combined vial of insulin and GLP-1 RA, Xultophy [14]. It shows remarkable glucose-lowering effect and its 
administration has been increasing [15]. We have currently an experience of a patient with type 2 
diabetes mellitus (T2DM), who showed remarkable effect of Xultophy. Then, the analyzed data on CGM 




History of Present Illness: Current case is 50-year-old female patient with T2DM, who has medical 
history of 10 years of duration. As to diabetic therapy, she has been provided insulin treatment for long. 
Her control status has not been so satisfactory, where HbA1c persisted about 7.4 – 8.7% so far. In order to 
make diabetic control better, we investigated her glucose variability by using FreeStyle Libre.  
  
Physical examination: She had no remarkable status in the physical examination, or no remarkable 
abnormalities of consciousness disorders from hypo- or hyperglycemia. Her vital signs were normal, and 
her body mass index (BMI) has been 21.5 kg/m2. She has slight numbness in the extremities, which is 
supposed to be diabetic neuropathy. However, she did not have retinopathy, nephropathy or other 
macroangiopathic complications.  
 
Laboratory exam: The results of laboratory exams were shown in the following. The standard 
biochemical data were AST 21 U/mL, ALT 24 U/mL, r-GT 25 U/mL, BUN 17 mg/dL, Cre 0.6 mg/dL, Uric 
Acid 5.5 mg/dL, HDL 39 mg/dL, LDL 102 mg/dL, postprandial TG 351 mg/dL, WBC 6300 /μL, RBC 4.45 x 
106/μL, Hb 13.5 g/dL, Plt 26.2 x 104/μL. Data related diabetes were HbA1c 7.9%, pre-prandial glucose 
157 mg/dL.  
 
Insulin therapy: For insulin treatment, she has been provided for years by the method of multiple daily 
insulin injection (MDI). She was given two kinds of insulin with four times a day. The insulin agents were 
Novo rapid (Novo Nordisk) provided 3 times a day just before 3 regular meals, and insulin Glargine (Eli 
Lilly and Company) one per day at night approximately at 2100h. For last weeks, her dose amount of 
rapid insulin was 21, 19, 18 units of Novo rapid and 15 units of Glargine. 
 
Application of Xultophy: For new application of Xultophy, she was given Xultophy once at 2100h, 
instead of previous Glargine. The protocol was as follows: Glargine 15 units on June 25-28 (day 1-4), 
Zultophy 8 units on June 29-30 (day 5-6), 10 units on July 1 and 2 (day 7-8), 11 units on July 3-4 (day 
9-10), 12 units after July 5 (after day 11)  
 
Methods 
In this case, the detail glucose variability was measured by using by FreeStyle Libre (Abbott, USA) [16]. 
Her blood glucose daily profile was investigated for 2 weeks. As to continuous glucose monitoring (CGM), 
FreeStyle Libre (Abbott, USA) has been known which shows stable reliability for blood glucose [17]. It can 
show beneficial results such as point accuracy, trend accuracy, and the stability of the sensor, alarms, 
calibration, time lag and traceability [18]. It also revealed satisfactory results for the guideline of Clinical 
and Laboratory Standards Institute (CLSI) [19].  
 
Results  
The case has used CGM apparatus FreeStyle Libre satisfactory for 2 weeks. The results of blood glucose 
daily profiles are shown in Figure 1. It shows gradually improving glucose variability. Glucose variability 
showed rather unstable on day 3 and 5 giving Glargine 15 units at 2100h. Glucose variability on day 6 and 
8 became more stable than before, during Xultophy 8 and 10 units. Glucose variability on 10 and 13 
became more stable, during Xultophy 11 and 12 units.  
 
The average blood glucose per day on day 3, 5, 6, 8, 10 and 13 showed 174, 164, 125, 111, 101 and 98 
mg/dL, respectively. The software of FreeStyle Libre can calculate HbA1c value from the data of daily 
blood glucose. Estimated HbA1c value was 6.2% and/or 44 mmol/mol. On the other hand, HbA1c value in 









In recent years, CGM has been rather prevalent in the diabetic practice [20]. Originally, it was a 
sensor-based device for diabetic patients. One of the most famous apparatus is FreeStyle Libre, which is 
produced by Abbott diabetes Care Inc., US [16]. It was evaluated to be reliable for long years, because it 
has simple function and good mechanism for obtaining blood glucose variability. Further, it is also useful 




Figure 1: - The changes in the profile of blood glucose using FreeStyle Libre  
 
In current study, some difference of HbA1c value was found between 7.9% in out clinic and 6.2% 
calculated by the software of FreeStyle libre. There was similar report like this situation [21]. One of the 
reasons for this phenomenon would be that CGM would not detect occasional acute increasing spike in 
blood glucose. As a matter of fact, blood glucose values are calculated in every 7.5 to 15 minutes in 
FreeStyle Libre and also FreeStyle Libre Pro devices [22]. These problems will be investigated from 
several points of view. 
 
In this study, the case has changed the injective vial from Glargin to Xultophy. Xultophy includes 
combination of insulin and GLP-1 RA. As to doses of the Xultophy, 1 dose contains insulin degludec 1 unit 
and liraglutide 0.036 mg [14]. It is usually injected to the patients from 10 to 50 units. One Xultophy pen 
is prefilled by 300 doses of Xultophy 100/3.6. It means insulin degludec 300 units, and liraglutide 10.8 mg. 
The pen has no push-button extension or the doses button does not extend during the dialing behavior 
the amount [14]. The usually regimen reveals once-daily administration, and it shows less frequencies of 
weight gain or hypoglycemia in comparison with other intensive insulin treatment methods. In addition, 
it has less gastrointestinal reverse effects when compared with those of GLP-1 RA administration alone 
[14, 15].    
 
In this case, Xultophy was firstly injected at 2100h on June 29. Her daily profile of blood glucose was 
improved after that. Average blood glucose has also gradually decreased from 164 mg/dL to 98 mg/dL. 
Consequently, this case showed remarkably good response for Xultophy. It suggests that pancreas 
function may be preserved for the stimulus of GLP-1 RA. Authors had recently a similar case treated by 
Xultophy with remarkable improvement of glucose variability [23]. The case was 79-year-old female with 
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probable secondary diabetes due to steroid administration. Clinically rapid reduction of HbA1c suggested 
the presence of preserved pancreas function.  
 
There are currently two standard guidelines for diabetes mellitus. They are the American Diabetes 
Association (ADA) Standards of Medical Care in Diabetes—2020 [24] (American) and also the 2019 
“Consensus Statement by the American Association of Clinical Endocrinologists (AACE) / American 
College of Endocrinology (ACE) on the Comprehensive Type 2 Diabetes Management Algorithm” [25] 
(Garber-2019). Both guidelines have comments for the recommendation to physicians in charge. It is the 
necessity to consider the combination of injection treatment for post-prandial hyperglycemia in the 
diabetic cases who reveal fundamental insulin doses 0.5 units/kg/day with higher HbA1c level [24] 
(American-2020). Consequently, we can always consider the adequate treatment for various diabetic 
patients with insulin, GLP-1 RA, and other OHAs in the future practice and research. 
 
In summary, this article described a diabetic case with clinical remarkable improvement by Xultophy. The 
glucose variability was investigated by CGM using FreeStyle Libre. These detail data would hopefully 
become some reference for future diabetic practice and research.  
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